TON Strategy Co — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that TON Strategy Co filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2018 | Dec 31, 2018 | $32.0K | Feb 7, 2019 |
| FY2018 | Dec 31, 2017 | $6.0K | Feb 7, 2019 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $12.78M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $895.0K | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $63.0K | Mar 25, 2025 |
| FY2023 | Dec 31, 2022 | $8.0K | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $10.52M | Apr 17, 2023 |
| FY2021 | Dec 31, 2020 | $9.97M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $9.10M | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | $32.0K | Jun 4, 2020 |
Revenue (Net Sales)
Net sales revenue — gross revenue less returns, allowances, and discounts. Used by many manufacturers and retailers as the primary top-line figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Dec 31, 2017 | $5.9K | Apr 2, 2018 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2022 | Dec 31, 2022 | $6.12M | Apr 17, 2023 |
| FY2022 | Dec 31, 2021 | $6.02M | Apr 17, 2023 |
| FY2021 | Dec 31, 2020 | $5.16M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $4.23M | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | ($20.0K) | Jun 4, 2020 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($148.48M) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | ($10.33M) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | ($21.99M) | Mar 25, 2025 |
| FY2023 | Dec 31, 2022 | ($37.44M) | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | ($34.49M) | Apr 17, 2023 |
| FY2021 | Dec 31, 2020 | ($24.96M) | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | ($15.92M) | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | ($12.13M) | Jun 4, 2020 |
| FY2018 | Dec 31, 2017 | ($7.27M) | Feb 7, 2019 |
| FY2017 | Dec 31, 2016 | ($4.27M) | Apr 2, 2018 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($36.44M) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | ($11.64M) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | ($13.80M) | Mar 25, 2025 |
| FY2023 | Dec 31, 2022 | ($18.87M) | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | ($33.71M) | Apr 17, 2023 |
| FY2021 | Dec 31, 2020 | ($24.74M) | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | ($15.83M) | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | ($7.79M) | Jun 4, 2020 |
| FY2018 | Dec 31, 2017 | ($4.71M) | Feb 7, 2019 |
| FY2017 | Dec 31, 2016 | ($3.13M) | Apr 2, 2018 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2022 | Dec 31, 2022 | $5.19M | Apr 17, 2023 |
| FY2022 | Dec 31, 2021 | $12.35M | Apr 17, 2023 |
| FY2021 | Dec 31, 2020 | $7.93M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $4.31M | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | $980.0K | Jun 4, 2020 |
| FY2018 | Dec 31, 2017 | $375.0K | Feb 7, 2019 |
| FY2017 | Dec 31, 2016 | $257.8K | Apr 2, 2018 |
| FY2016 | Dec 31, 2015 | $241.6K | Mar 31, 2017 |
| FY2015 | Dec 31, 2014 | $156.8K | Mar 30, 2016 |
| FY2014 | Dec 31, 2013 | $485.4K | Mar 31, 2015 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2021 | Dec 31, 2020 | $1.04M | Mar 31, 2022 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($20.77M) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | ($8.77M) | Mar 31, 2026 |
| FY2022 | Dec 31, 2022 | ($19.41M) | Apr 17, 2023 |
| FY2022 | Dec 31, 2021 | ($25.86M) | Apr 17, 2023 |
| FY2021 | Dec 31, 2020 | ($16.29M) | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | ($8.12M) | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | ($4.16M) | Jun 4, 2020 |
| FY2018 | Dec 31, 2017 | ($1.68M) | Feb 7, 2019 |
| FY2016 | Dec 31, 2016 | $1.60M | Mar 31, 2017 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $88.0K | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $342.0K | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $32.0K | Mar 25, 2025 |
| FY2023 | Dec 31, 2022 | $20.0K | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $26.0K | Apr 17, 2023 |
| FY2021 | Dec 31, 2020 | $317.0K | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $146.0K | Mar 31, 2021 |
| FY2017 | Dec 31, 2016 | $2.5K | Apr 2, 2018 |
| FY2016 | Dec 31, 2015 | $62.0K | Mar 31, 2017 |
| FY2015 | Dec 31, 2014 | $110.8K | Mar 30, 2016 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $411.16M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $20.64M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $10.84M | Mar 25, 2025 |
| FY2023 | Dec 31, 2022 | $24.49M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $34.43M | Apr 17, 2023 |
| FY2021 | Dec 31, 2020 | $32.54M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $28.36M | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | $898.0K | Jun 4, 2020 |
| FY2018 | Dec 31, 2017 | $92.0K | Feb 7, 2019 |
| FY2017 | Dec 31, 2016 | $104.2K | Apr 2, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $4.77M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $4.61M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $7.71M | Mar 25, 2025 |
| FY2023 | Dec 31, 2022 | $19.33M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $21.11M | Apr 17, 2023 |
| FY2021 | Dec 31, 2020 | $21.80M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $16.91M | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | $5.95M | Jun 4, 2020 |
| FY2018 | Dec 31, 2017 | $5.88M | Feb 7, 2019 |
| FY2016 | Dec 31, 2016 | $3.57M | Mar 31, 2017 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $406.49M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $16.20M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $3.13M | Mar 25, 2025 |
| FY2023 | Dec 31, 2022 | $5.17M | Apr 1, 2024 |
| FY2023 | Dec 31, 2021 | $13.32M | Apr 1, 2024 |
| FY2022 | Dec 31, 2020 | $10.75M | Apr 17, 2023 |
| FY2021 | Dec 31, 2019 | $11.45M | Mar 31, 2022 |
| FY2020 | Dec 31, 2018 | ($5.06M) | Mar 31, 2021 |
| FY2019 | Dec 31, 2017 | ($5.79M) | Jun 4, 2020 |
| FY2018 | Dec 31, 2016 | ($3.47M) | Feb 7, 2019 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $5.17M | Mar 31, 2026 |
| FY2023 | Dec 31, 2022 | $9.58M | Apr 1, 2024 |
| FY2023 | Dec 31, 2021 | $19.76M | Apr 1, 2024 |
| FY2022 | Dec 31, 2020 | $20.06M | Apr 17, 2023 |
| FY2021 | Dec 31, 2019 | $16.34M | Mar 31, 2022 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($336.73M) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | ($187.09M) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | ($175.62M) | Mar 25, 2025 |
| FY2023 | Dec 31, 2022 | ($153.46M) | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | ($116.03M) | Apr 17, 2023 |
| FY2021 | Dec 31, 2020 | ($81.54M) | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | ($56.59M) | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | ($40.67M) | Jun 4, 2020 |
| FY2018 | Dec 31, 2017 | ($28.54M) | Feb 7, 2019 |
| FY2017 | Dec 31, 2016 | ($21.27M) | Apr 2, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $39.49M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $7.62M | Mar 31, 2026 |
| FY2022 | Dec 31, 2022 | $2.43M | Apr 17, 2023 |
| FY2022 | Dec 31, 2021 | $937.0K | Apr 17, 2023 |
| FY2021 | Dec 31, 2020 | $1.82M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $983.0K | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | $634.0K | Jun 4, 2020 |
| FY2018 | Dec 31, 2017 | $11.0K | Feb 7, 2019 |
| FY2017 | Dec 31, 2016 | $16.8K | Apr 2, 2018 |
| FY2017 | Dec 31, 2015 | $103.0K | Apr 2, 2018 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (5) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | (19) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | (441) | Mar 25, 2025 |
| FY2023 | Dec 31, 2022 | (6) | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Apr 17, 2023 |
| FY2013 | Nov 30, 2013 | 0 | Feb 28, 2014 |
| FY2013 | Nov 30, 2012 | 0 | Feb 28, 2014 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (5) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | (19) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | (441) | Mar 25, 2025 |
| FY2023 | Dec 31, 2022 | (6) | Apr 1, 2024 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 56.53M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | 993,120 | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | 106,157 | Mar 25, 2025 |
| FY2023 | Dec 31, 2022 | 2.92M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | 72.94M | Apr 17, 2023 |
| FY2021 | Dec 31, 2020 | 47.80M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | 24.50M | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | 12.06M | Jun 4, 2020 |
| FY2018 | Dec 31, 2017 | 7.94M | Feb 7, 2019 |
| FY2017 | Dec 31, 2016 | 94.66M | Apr 2, 2018 |